Trialsmuc1peptide vaccinepoly-iclcnsclc

MUC1 peptide vaccine trial recruiting in non-small cell lung cancer

The Phase 1/2 study pairs a MUC1 100mer peptide with Poly-ICLC adjuvant in localized and locally advanced NSCLC, with boosters out to 10 years.

By Priya Raman · Science Reporter

Oct 26 08:00 ETSource: ClinicalTrials.gov

The wire

01NCT01720836, sponsored by Olivera Finn and started in November 2012, gives subcutaneous MUC1 peptide-Poly-ICLC vaccine every three weeks for three doses, with optional yearly boosters for confirmed responders.
02The same MUC1 100mer plus Poly-ICLC formulation is being tested in castrate-resistant prostate cancer and advanced colonic adenomas, with no toxicity reported to date.
03The primary aim is characterizing the anti-MUC1 immune response rather than efficacy; the listing reports recruiting status only.

From the source

Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
NCT01720836 · PHASE1/PHASE2 · RECRUITING · Sponsor: Olivera Finn · Conditions: Non-small Cell Lung Cancer (NSCLC).

Read at clinicaltrials.gov

Source URL https://clinicaltrials.gov/study/NCT01720836